Prevalence and outcome of COVID-19 among Iranian celiac patients
Gastroenterology and Hepatology from Bed to Bench,
Vol. 15 No. 2 (2022),
15 March 2022
https://doi.org/10.22037/ghfbb.vi.2569
Abstract
Aim: This study aimed to evaluate the prevalence and outcome of COVID-19 among Iranian celiac disease patients.
Background: Patients with celiac disease (CD) might be at greater risk for opportunistic viral infections. Coronavirus disease-2019 (COVID-19) is a new coronavirus (SARS-CoV-2) cause of respiratory disorder which spread around the world at the end of 2019. The question is does COVID-19 infection increase the risk of severe outcome and/or a higher mortality in treated celiac disease?.
Methods: Data regarding demographic details, clinical history, and COVID-19 infection symptoms among treated celiac disease patients was collected from July 2020 to January 2021 and analyzed using SPSS version 25.
Results A total of 455 celiac disease patients were included in this study. The prevalence of Covid-19 infection among celiac disease patients was 2.4%. Infection among women (72.7%) was higher than the men, and only one overweight man who smoked was hospitalized. Among COVID-19 infected celiac disease patients, the most common symptoms were myalgia 90.9% (10/11), fever, body trembling, headache, shortness of breath, loss of smell and taste, and anorexia (72.7%). Treatments for COVID-19, included antibiotics (90.9%), pain analgesics (54.5%), antihistamines (27.3%), antivirals (9.1%) and hydroxychloroquine (9.1%).
Conclusion: This study shows that treated celiac disease is not a risk factor for severity or higher mortality in patients infected with COVID-19. Women, however, might need extra-protection to prevent COVID-19 infection.
- Covid-19
- Celiac disease
- SARS-CoV-2
- Infections
How to Cite
References
Gujral N, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012;18:6036.
Gholam Mostafaei FS, Rostami-Nejad M, Emadi A, Yadegar A, Asadzadeh Aghdaei H, Zali MR. Changes in the composition and function of the gut microbiota in celiac disease. Koomesh 2021;23:301-16.
Cheung KS, Hung IF, Chan PP, Lung K, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020;159:81-95.
Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol 2020;15:630-45.
Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2021;72:340-50.
Arman A, Tajik M, Nazemipour M, Ahmadinejad Z, Shahrestanaki SK, Hazrati E, et al. Risk factors of developing critical conditions in Iranian patients with COVID-19. Glob Epidemiol 2021;3:100046.
Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 2020;19:102575.
Asri N, Nazemalhosseini Mojarad E, Mirjalali H, Mohebbi SR, Baghaei K, Rostami-Nejad M, et al. Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 Rα), FOXP3 and IL-6 expressions as genes affecting immune homeostasis. BMC Gastroenterol 2021;21:462.
Mårild K, Fredlund H, Ludvigsson JF. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. Am J Gastroenterol 2010;105:2465-73.
Zingone F, D'Odorico A, Lorenzon G, Marsilio I, Farinati F, Savarino EV. Risk of COVID-19 in celiac disease patients. Autoimmun Rev 2020;19:102639.
Gokden Y, Hot S, Adas M, Koc DO, Atak S, Hot A. Celiac disease and COVID-19 pandemic: Should we worry. Acta Gastro-Enterol Belg 2020;83:517-25.
Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol 2020;127:104378.
Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health 2020;8:152.
Lebwohl B, Larsson E, Söderling J, Roelstraete B, Murray JA, Green PH, et al. Risk of severe covid-19 in patients with celiac disease: A population-based cohort study. Clin Epidemiol 2021;13:121.
Engin AB, Engin ED, Engin A. Two important controversial risk factors in SARS-CoV-2 infection: obesity and smoking. Environ Toxicol Pharmacol 2020;78:103411.
Gholam-Mostafaei FS, Didari T, Ramandi M, Vafaee R, Nejad MR. Gut microbiota, Angiotensin-converting enzyme, celiac disease and risk of COVID-19 infection; a review. Gastroenterol Hepatol Bed Bench 2021;14:S24-S31.
Cai H, Yang L, Lu Y, Zhang S, Ye C, Zhang X, et al. High body mass index is a significant risk factor for the progression and prognosis of imported COVID-19: a multicenter, retrospective cohort study. BMC Infect Dis 2021;21:1-11.
Weng L-M, Su X, Wang X-Q. Pain symptoms in patients with coronavirus disease (COVID-19): a literature review. J Pain Res 2021;14:147.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
Muller L, Gorter K, Hak E, Goudzwaard W, Schellevis F, Hoepelman I, et al. Increased risk of infection in patients with diabetes mellitus type 1 or 2. Ned Tijdschr Geneeskd 2006;150:549-53.
Kylökäs A, Kaukinen K, Huhtala H, Collin P, Mäki M, Kurppa K. Type 1 and type 2 diabetes in celiac disease: prevalence and effect on clinical and histological presentation. BMC Gastroenterol 2016;16:1-7.
Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021;17:11-30.
Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an overview of existing evidence. BMJ Open Respir Res 2021;8:e000806.
Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:605-12.
- Abstract Viewed: 147 times
- PDF Downloaded: 120 times